MUMPS
MCID: MMP001
MIFTS: 57

Mumps (MUMPS)

Categories: Ear diseases, Endocrine diseases, Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps 12 74 52 54 42 3 43 15 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:10264
ICD9CM 34 072
MeSH 43 D009107
NCIt 49 C29888
SNOMED-CT 67 36989005
ICD10 32 B26 B26.8 B26.9
UMLS 71 C0026780

Summaries for Mumps

MedlinePlus : 42 Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection and acute disseminated encephalomyelitis, and has symptoms including fever and pruritus. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Bleomycin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include testes, salivary gland and skin, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A viral infectious disease that results in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC : 3 Mumps is a contagious disease that is caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite. Then most people will have swelling of their salivary glands. This is what causes the puffy cheeks and a tender, swollen jaw.

Wikipedia : 74 Mumps is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever,... more...

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 733)
# Related Disease Score Top Affiliating Genes
1 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 34.4 STAT2 IFNAR2
2 acute disseminated encephalomyelitis 32.9 IL10 HLA-DRB1 CD40LG
3 rubella 31.4 TNF TLR3 IL6 IL2 IL10 IFNG
4 aseptic meningitis 31.3 TNF IL10 IFNG CD40LG
5 newcastle disease 31.2 TNF TLR3 IRF1 EIF2AK2
6 meningoencephalitis 31.2 TNF IL6 IL10 CD40LG
7 orchitis 31.1 TNF IL6 IL2 IL10 CD40LG
8 diphtheria 31.0 TNF IL2 IFNG CD40LG
9 poliomyelitis 31.0 TNF IL10 IFNG CD40LG
10 pertussis 31.0 TNF IRF1 IL6 IL10
11 measles 31.0 TNF TLR3 STAT2 STAT1 IL6 IL2
12 guillain-barre syndrome 31.0 TNF HLA-DRB1 CD40LG
13 viral meningitis 30.9 IL6 IFNG CD40LG
14 purpura 30.8 TNF IL6 IL10 CD40LG
15 encephalitis 30.8 TNF TLR3 MX1 IL6 IL10 CD40LG
16 transverse myelitis 30.8 TNF IL6 IL10
17 herpes simplex 30.7 TNF TLR3 STAT1 EIF2AK2
18 optic neuritis 30.7 TNF IL10 HLA-DRB1
19 allergic hypersensitivity disease 30.6 TNF IL2 IL10 IFNG
20 iritis 30.6 TNF IL6 CD40LG
21 meningitis 30.6 TNF IL6 IL2 IL10 IFNG CD46
22 exanthem 30.5 TNF IL6 IL2 IL10 CD40LG
23 neuritis 30.5 TNF IL6 IL10 IFNG
24 acute transverse myelitis 30.5 IL6 IL10
25 recurrent respiratory papillomatosis 30.5 IL2 HLA-DRB1
26 venezuelan equine encephalitis 30.4 STAT2 STAT1 IRF1 IFNG
27 chickenpox 30.4 TNF TLR3 STAT1 IL6 IL2 IL10
28 tetanus 30.4 TNF IL6 IL2 IL10 IFNG CD40LG
29 chronic graft versus host disease 30.4 IL10 IFNG
30 iridocyclitis 30.4 TNF IL6 CD40LG
31 thyroiditis 30.4 TNF IL6 IL2 IL10
32 yellow fever 30.3 STAT1 IL6 CD40LG
33 keratitis, hereditary 30.3 TNF TLR3 IL6 IL10
34 plague 30.3 TNF IL6 IL10
35 rabies 30.3 TLR3 STAT2 STAT1 MX1 CD40LG
36 arthritis 30.2 TNFRSF1A TNF IL6 IL10 IFNG HLA-DRB1
37 pleurisy 30.2 TNF IL2 IFNG
38 myelitis 30.2 TNFRSF1A TNF IL6 IL10 HLA-DPB1 CD40LG
39 neuroretinitis 30.2 IFNG CD40LG
40 vaccinia 30.2 TNF STAT2 STAT1 IL6 IL2 EIF2AK2
41 food allergy 30.2 TNF IL10 IFNG
42 hepatitis a 30.2 TNF TLR3 IL2 IL10 IFNG
43 myositis 30.1 TNF IL6 IL2 IFNG HLA-DRB1
44 smallpox 30.1 TNF IRF1 IL2 IFNG
45 crohn's colitis 30.0 TNF IL2 IFNG
46 gastroenteritis 30.0 TNF IL6 IL10 IFNG
47 combined t cell and b cell immunodeficiency 30.0 IL6 IL2 IL10 CD40LG
48 urethritis 30.0 TNF IL6 CD40LG
49 herpes zoster 30.0 TNF IL2 IL10 IFNG HLA-DRB1 CD40LG
50 acute myocarditis 30.0 TLR3 STAT1 IL6 IL10

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps

Symptoms & Phenotypes for Mumps

UMLS symptoms related to Mumps:


fever, pruritus

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CD40LG EIF2AK2 IL10 IL2 MX1 RIPK1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CD40LG EIF2AK2 IL10 IL2 MX1 RIPK1

MGI Mouse Phenotypes related to Mumps:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 CD40LG EIF2AK2 IFNAR2 IFNG IL10 IL2
2 cardiovascular system MP:0005385 10.27 CD40LG CD46 IFNG IL10 IL2 IL6
3 cellular MP:0005384 10.26 CD40LG EIF2AK2 IFNG IL10 IL2 IL6
4 immune system MP:0005387 10.24 CD40LG EIF2AK2 IFNAR2 IFNG IL10 IL2
5 endocrine/exocrine gland MP:0005379 10.17 CD40LG IFNG IL10 IL2 IL6 IRF1
6 digestive/alimentary MP:0005381 10.06 IFNG IL10 IL2 IL6 RIPK1 STAT1
7 mortality/aging MP:0010768 10.03 CD40LG EIF2AK2 IFNAR2 IFNG IL10 IL2
8 integument MP:0010771 9.97 CD40LG IFNG IL10 IL6 IRF1 RIPK1
9 liver/biliary system MP:0005370 9.86 IFNG IL10 IL2 IL6 RIPK1 STAT1
10 muscle MP:0005369 9.56 IFNG IL10 IL6 IRAK1 STAT1 TLR3
11 neoplasm MP:0002006 9.36 EIF2AK2 IFNAR2 IFNG IL10 IL2 IL6

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
3 Liver Extracts Phase 4
4 Vaccines Phase 4
5 Immunologic Factors Phase 4
6 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
7 Gastrointestinal Agents Phase 4
8 Cathartics Phase 4
9 Laxatives Phase 4
10 insulin Phase 4
11 Insulin, Globin Zinc Phase 4
12 Antiviral Agents Phase 4
13
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
14
Podophyllin Approved Phase 3 9000-55-9
15
Petrolatum Approved, Investigational Phase 3 8009-03-8
16 Hemagglutinins Phase 3
17 Somatomedin B Phase 3
18 PENTA Phase 3
19 Keratolytic Agents Phase 3
20
Altretamine Approved Phase 2 645-05-6 2123
21
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
23 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
24
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
25
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
26
Basiliximab Approved, Investigational Phase 1, Phase 2 179045-86-4, 152923-56-3
27
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
28
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
29
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
30 Antibodies Phase 2
31 Immunoglobulins Phase 2
32 Fibrinolytic Agents Phase 2
33 Anticoagulants Phase 2
34 Antibodies, Monoclonal Phase 2
35 Pharmaceutical Solutions Phase 2
36 Anti-Infective Agents Phase 1, Phase 2
37 Anti-Bacterial Agents Phase 1, Phase 2
38 Dermatologic Agents Phase 1, Phase 2
39 Antibiotics, Antitubercular Phase 1, Phase 2
40 Immunosuppressive Agents Phase 1, Phase 2
41 Antirheumatic Agents Phase 1, Phase 2
42 Analgesics Phase 2
43 Interleukin-2 Phase 2
44 Anti-Inflammatory Agents Phase 1, Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Thymoglobulin Phase 1, Phase 2
47 Methylprednisolone Acetate Phase 1, Phase 2
48 Antiemetics Phase 1, Phase 2
49 Antitubercular Agents Phase 1, Phase 2
50 Hormone Antagonists Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Unknown status NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
2 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
3 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Unknown status NCT01770119 Phase 4
4 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
5 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
6 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
7 Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
8 An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age Completed NCT00312858 Phase 4
9 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
10 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
11 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
12 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
13 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
14 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
15 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
16 A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months Completed NCT02253407 Phase 4
17 The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection Completed NCT03453801 Phase 4
18 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
19 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
20 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
21 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
22 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
23 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
24 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
25 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
26 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
27 A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children Completed NCT00092430 Phase 3
28 Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life Completed NCT00127023 Phase 3
29 Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life Completed NCT00127010 Phase 3
30 A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP) Completed NCT01536405 Phase 3
31 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
32 A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age Completed NCT00092391 Phase 3
33 A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
34 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers Completed NCT00626327 Phase 3
35 Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan. Completed NCT01188343 Phase 3
36 An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life Completed NCT00560755 Phase 3
37 Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®. Completed NCT00406211 Phase 3
38 Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children Completed NCT01506193 Phase 3
39 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT00109343 Phase 3
40 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months Completed NCT00402831 Phase 3
41 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762) Completed NCT01621802 Phase 3
42 Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Completed NCT00197015 Phase 3
43 A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children Completed NCT00975507 Phase 3
44 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762) Completed NCT02058563 Phase 3
45 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
46 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age Completed NCT00432042 Phase 3
47 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects 12 to 18 Months of Age Completed NCT00432523 Phase 3
48 Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Completed NCT00226499 Phase 3
49 Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
50 Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age Completed NCT00985166 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

MalaCards organs/tissues related to Mumps:

40
Testes, Salivary Gland, Skin, T Cells, Heart, Thyroid, Bone

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 7959)
# Title Authors PMID Year
1
Mumps. 61 42
31503310 2019
2
Mumps update: What nurses need to know. 61 42
30893199 2019
3
Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study. 61 42
30843921 2019
4
Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation. 54 61
18567898 2008
5
Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. 54 61
16051811 2005
6
Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1. 54 61
12917439 2003
7
[The rapid detection kit based on neuraminidase activity of influenza virus]. 54 61
11225310 2000
8
Poor induction of interferon-induced 2',5'-oligoadenylate synthetase (2-5 AS) in cells persistently infected with mumps virus is caused by decrease of STAT-1 alpha. 54 61
9856085 1998
9
Investigation of IFN type-I receptor and IFN regulatory factor expression relating to induction of 2', 5'-oligoadenylate synthetase in cells persistently infected with the mumps virus. 54 61
8981353 1996
10
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
11
Health Departments' Experience With Mumps Outbreak Response and Use of a Third Dose of Measles, Mumps, and Rubella Vaccine. 61
30807465 2020
12
CDC Guidance for Use of a Third Dose of MMR Vaccine During Mumps Outbreaks. 61
30789597 2020
13
Cost of Responding to the 2017 University of Washington Mumps Outbreak: A Prospective Analysis. 61
30807459 2020
14
Responding to a Mumps Outbreak Impacting Immigrants and Low-English-Proficiency Populations. 61
31592985 2020
15
A 13-Year-Old Boy Who Has Kawasaki Disease Shock Syndrome Presents with Parotitis. 61
31984160 2020
16
Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany. 61
31879123 2020
17
Seroprevalence of measles, mumps, and rubella and genetic characterization of mumps virus in Khartoum, Sudan. 61
31759167 2020
18
Assessment of the Clinical and Economic Impact of Different Immunization Protocols of Measles, Mumps, Rubella and Varicella in Internationally Adopted Children. 61
32024209 2020
19
Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-class Antibodies to Measles, Mumps, Rubella and Varicella-Zoster Viruses in Presumptively Immune Healthcare Workers. 61
32024728 2020
20
Intralesional Injection of Measles, Mumps, Rubella Vaccine versus Cryotherapy in Treatment of Warts: A Randomized Controlled Trial. 61
32031726 2020
21
2016-2017 Arkansas mumps outbreak in a close-knit community: Assessment of the economic impact and response strategies. 61
31818532 2020
22
Antibody response to vaccination after haematopoietic cell transplantation in children using a reduced dose schedule-A retrospective cohort study. 61
31617270 2020
23
Application of a fast and cost-effective 'three-in-one' MMR ELISA as a tool for surveying anti-MMR humoral immunity: the Hungarian experience. 61
32014073 2020
24
Hepatitis B Birth Dose Effects on Childhood Immunization in the U.S. 61
31959321 2020
25
Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. 61
31682981 2020
26
Bacterial, viral, and fungal infection-related risk of Parkinson's disease: Meta-analysis of cohort and case-control studies. 61
32017453 2020
27
Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data. 61
31791812 2020
28
How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers. 61
30024308 2020
29
Congenital viral infections in England over five decades: a population-based observational study. 61
31708420 2020
30
Why are vaccines against many human viral diseases still unavailable; an historic perspective? 61
31502669 2020
31
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 61
31870573 2020
32
Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. 61
31919861 2020
33
Iodide mumps: A rare complication of iodine-containing contrast after coronary angioplasty. 61
32011325 2020
34
An efficient, reproducible and accurate RT-qPCR based method to determine mumps specific neutralizing antibody. 61
31911119 2020
35
Structural basis for Glycan-receptor binding by mumps virus hemagglutinin-neuraminidase. 61
32005959 2020
36
Hypersensitivity reactions to measles-mumps-rubella vaccine in patients with IgE-mediated cow's milk allergy. 61
31319219 2020
37
Ongoing mumps outbreak among adolescents and young adults, Ireland, August 2018 to January 2020. 61
32019666 2020
38
High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China. 61
31977281 2020
39
Mumps antibodies in the cord blood: Association with maternal recall of mumps. Possible consequences for vaccination strategies. 61
31767464 2020
40
Identification of Naturally Processed Mumps Virus Epitopes by Mass Spectrometry: Confirmation of Multiple CD8+ T-Cell Responses in Mumps Patients. 61
31560392 2020
41
Intralesional measles-mumps-rubella is associated with a higher complete response in cutaneous warts: a systematic review and meta-analysis of randomized controlled trial including GRADE qualification. 61
31985307 2020
42
Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age. 61
31732325 2020
43
Immunization Status against Measles, Mumps, Rubella and Varicella in a Large Population of Internationally Adopted Children Referred to Meyer Children's University Hospital from 2009 to 2018. 61
32013010 2020
44
Healthcare utilisation and measles, mumps and rubella vaccination rates among children with an extended postnatal home visiting programme in a disadvantaged area in Stockholm, Sweden-A 3-year follow-up. 61
31957046 2020
45
Intralesional immunotherapy for pediatric warts: A review. 61
31930595 2020
46
Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. 61
31987692 2020
47
The Impact of Pharmacist Vaccination Privilege during a Nation-Wide Measles Outbreak. 61
31936563 2020
48
Measles re-emerges and recommendation of vaccination. 61
31569091 2020
49
The Impact of Mandatory Vaccination Law in Italy on MMR Coverage Rates in Two of the Largest Italian Regions (Emilia-Romagna and Sicily): An Effective Strategy to Contrast Vaccine Hesitancy. 61
32019092 2020
50
Vaccination Programs for Adults in Europe, 2019. 61
31968652 2020

Variations for Mumps

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
2
Show member pathways
13.92 TNFRSF1A TNF STAT2 STAT1 RIPK1 IRAK1
3
Show member pathways
13.67 TNFRSF1A TNF STAT2 STAT1 RIPK1 IRF1
4
Show member pathways
13.54 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
5
Show member pathways
13.36 TNFRSF1A TNF TLR3 STAT2 STAT1 IRAK1
6
Show member pathways
13.1 TNFRSF1A TNF TLR3 STAT2 STAT1 MX1
7
Show member pathways
13.07 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
8
Show member pathways
13.04 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
9
Show member pathways
13.01 TNF STAT1 IL6 IL2 IL10 IFNG
10 12.95 STAT2 STAT1 IL6 IL2 IFNG IFNAR2
11
Show member pathways
12.88 TNF TLR3 RIPK1 IRF1 IL6 IFNG
12
Show member pathways
12.87 TNFRSF1A TNF RIPK1 IRF1 IRAK1
13
Show member pathways
12.86 TNFRSF1A TNF TLR3 RIPK1 IRAK1 IL6
14
Show member pathways
12.84 TNFRSF1A TNF STAT1 IL6 IL2
15
Show member pathways
12.83 TNFRSF1A TNF STAT1 RIPK1 IFNG EIF2AK2
16 12.79 TNFRSF1A TNF TLR3 STAT2 STAT1 IRAK1
17
Show member pathways
12.77 TNF STAT1 IL6 IL2 IL10 IFNG
18
Show member pathways
12.77 TNF STAT1 IL6 IL2 IL10 IFNG
19
Show member pathways
12.76 TNF STAT1 RIPK1 IL6 IL2 IL10
20
Show member pathways
12.76 TNFRSF1A TNF IL2 IL10 IFNG IFNAR2
21
Show member pathways
12.73 TNFRSF1A TNF TLR3 RIPK1 IRAK1 CD40LG
22
Show member pathways
12.68 STAT2 STAT1 MX1 IRF1 IFNG IFNAR2
23
Show member pathways
12.64 TNFRSF1A TNF STAT2 STAT1 MX1 IRF1
24
Show member pathways
12.57 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
25 12.52 TNFRSF1A TNF IL6 IL2 HLA-DRB1 HLA-DPB1
26
Show member pathways
12.51 STAT2 STAT1 IL6 IL2 IL10 IFNG
27
Show member pathways
12.49 TNF TLR3 STAT1 IRF1 IRAK1 IL6
28 12.48 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
29
Show member pathways
12.47 TNFRSF1A TNF IL6 IL2 IL10
30 12.44 TNFRSF1A TNF RIPK1 IRAK1 IL6
31
Show member pathways
12.43 STAT2 STAT1 IL6 IFNG IFNAR2
32
Show member pathways
12.41 TNF TLR3 RIPK1 IRAK1 IL6
33 12.41 TNF STAT2 STAT1 RIPK1 IL6 IFNAR2
34
Show member pathways
12.4 TNFRSF1A TNF STAT1 RIPK1
35
Show member pathways
12.4 TNF IL6 IL2 IFNG
36
Show member pathways
12.39 TNF STAT2 STAT1 IRF1 IL6 IL2
37
Show member pathways
12.39 TNF STAT2 STAT1 MX1 IRF1 IL6
38
Show member pathways
12.39 TNFRSF1A TNF STAT1 IRAK1 IL10 IFNG
39
Show member pathways
12.37 TNF STAT1 IRF1 IRAK1 IL6
40 12.36 TNFRSF1A TNF TLR3 STAT1 IL6 IFNG
41
Show member pathways
12.36 TNF STAT1 IRF1 IRAK1 IL6 IFNG
42 12.34 TNFRSF1A TNF STAT1 IRAK1 IL6 IL10
43 12.33 TNFRSF1A TNF RIPK1 CD40LG
44
Show member pathways
12.26 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
45 12.23 TNFRSF1A TNF STAT2 STAT1 IFNG IFNAR2
46
Show member pathways
12.21 TNF TLR3 STAT2 STAT1 IL6 IL2
47 12.19 TNF IRAK1 IL6 IL2 IL10
48 12.17 TNF STAT2 STAT1 IL6
49 12.17 TNF IL6 IL2 IL10 IFNG
50
Show member pathways
12.16 STAT1 IRAK1 IL2 IFNG HLA-DRB1

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.35 TLR3 RIPK1 IRAK1 HLA-DRB1 HLA-DPB1
2 cell surface GO:0009986 9.17 TNFRSF1A TNF TLR3 HLA-DRB1 HLA-DPB1 CD46

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 TNFRSF1A TLR3 STAT2 STAT1 RIPK1 MX1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF STAT1 IRF1 IRAK1 IL6 IL10
4 innate immune response GO:0045087 10.16 TLR3 MX1 IRF1 IRAK1 EIF2AK2 CD46
5 negative regulation of apoptotic process GO:0043066 10.16 IRAK1 IL6 IL2 IL10 EIF2AK2 CD40LG
6 positive regulation of gene expression GO:0010628 10.12 TNF TLR3 IL6 IFNG CD46
7 inflammatory response GO:0006954 10.1 TNFRSF1A TNF TLR3 IL6 IL10 CD40LG
8 immune response GO:0006955 10.1 TNF IL6 IL2 IL10 IFNG HLA-DRB1
9 adaptive immune response GO:0002250 10.09 IL2 IFNG HLA-DRB1 HLA-DPB1 CD46
10 viral process GO:0016032 10.03 TNFRSF1A STAT2 STAT1 RIPK1 IRAK1 HLA-DRB1
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.02 TNFRSF1A TNF TLR3 RIPK1 IRAK1
12 immune system process GO:0002376 10.02 TLR3 MX1 IRF1 IRAK1 IL2 HLA-DRB1
13 positive regulation of protein phosphorylation GO:0001934 10.01 TNF RIPK1 IL2 IFNG
14 cellular response to lipopolysaccharide GO:0071222 10 TNF IRAK1 IL6 IL10
15 tumor necrosis factor-mediated signaling pathway GO:0033209 9.97 TNFRSF1A TNF STAT1 RIPK1 CD40LG
16 defense response GO:0006952 9.95 TNFRSF1A TNF TLR3 STAT2 STAT1 MX1
17 positive regulation of inflammatory response GO:0050729 9.93 TNFRSF1A TNF TLR3 IL2
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNFRSF1A TNF IL6 IL2 IFNG
19 cellular response to mechanical stimulus GO:0071260 9.91 TNFRSF1A TLR3 IRF1
20 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.91 TNFRSF1A TNF TLR3 RIPK1
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF TLR3 IRAK1 EIF2AK2
22 interferon-gamma-mediated signaling pathway GO:0060333 9.91 STAT1 IRF1 IFNG HLA-DRB1 HLA-DPB1
23 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF STAT1 IRAK1 IL6
24 response to glucocorticoid GO:0051384 9.89 TNF IL6 IL10
25 apoptotic signaling pathway GO:0097190 9.89 TNF TLR3 RIPK1
26 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR3 IL6
27 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
28 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF TLR3 RIPK1 IFNG
29 positive regulation of type I interferon production GO:0032481 9.87 TLR3 IRF1 IRAK1
30 positive regulation of interferon-gamma production GO:0032729 9.86 TNF IL2 HLA-DPB1
31 negative regulation of viral genome replication GO:0045071 9.86 TNF MX1 EIF2AK2
32 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 IL10
33 JAK-STAT cascade GO:0007259 9.85 STAT2 STAT1 IFNG IFNAR2
34 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.84 TNFRSF1A TNF RIPK1
35 positive regulation of cytokine production GO:0001819 9.84 TNF TLR3 EIF2AK2
36 microglial cell activation GO:0001774 9.83 TNF TLR3 IFNG
37 positive regulation of interleukin-8 production GO:0032757 9.83 TNF TLR3 RIPK1
38 positive regulation of interleukin-12 production GO:0032735 9.83 TLR3 IFNG CD40LG
39 cellular response to interferon-beta GO:0035458 9.81 TLR3 STAT1 IRF1
40 positive regulation of T cell proliferation GO:0042102 9.8 IL6 IL2 HLA-DPB1 CD46 CD40LG
41 response to virus GO:0009615 9.8 TNF TLR3 MX1 IFNG IFNAR2 EIF2AK2
42 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF TLR3 RIPK1 IRAK1 IL6 EIF2AK2
43 positive regulation of chemokine biosynthetic process GO:0045080 9.77 TNF TLR3 IFNG
44 positive regulation of chemokine production GO:0032722 9.76 TNF TLR3 IL6 EIF2AK2
45 death-inducing signaling complex assembly GO:0071550 9.75 TNFRSF1A TNF RIPK1
46 positive regulation of ceramide biosynthetic process GO:2000304 9.73 TNFRSF1A TNF
47 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
48 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 IL10 IFNG
49 positive regulation of programmed cell death GO:0043068 9.73 TNF RIPK1
50 response to interferon-beta GO:0035456 9.73 STAT1 IFNAR2

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 UBQLN4 TNFRSF1A TNF TLR3 STAT2 STAT1
2 identical protein binding GO:0042802 9.56 UBQLN4 TNF TLR3 STAT2 STAT1 RIPK1
3 tumor necrosis factor receptor binding GO:0005164 9.33 TNF STAT1 CD40LG
4 cytokine activity GO:0005125 9.1 TNF IL6 IL2 IL10 IFNG CD40LG

Sources for Mumps

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....